Cargando…

Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement

The purpose of this study was to determine the percentage of patients discharged with a subtherapeutic INR <1.8 using our institutions inpatient warfarin dosing nomogram following total joint arthroplasty (TJA). We examined predisposing risk factors for a subtherapeutic discharge (INR <1.8), i...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Ryan, Stehli, Annamarie, Nguyen, Hiep, Leu, Szu-Yun, Nguyen, Danh V, Schwarzkopf, Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Open 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483539/
https://www.ncbi.nlm.nih.gov/pubmed/26157529
http://dx.doi.org/10.2174/1874325001509010129
_version_ 1782378578793463808
author Murphy, Ryan
Stehli, Annamarie
Nguyen, Hiep
Leu, Szu-Yun
Nguyen, Danh V
Schwarzkopf, Ran
author_facet Murphy, Ryan
Stehli, Annamarie
Nguyen, Hiep
Leu, Szu-Yun
Nguyen, Danh V
Schwarzkopf, Ran
author_sort Murphy, Ryan
collection PubMed
description The purpose of this study was to determine the percentage of patients discharged with a subtherapeutic INR <1.8 using our institutions inpatient warfarin dosing nomogram following total joint arthroplasty (TJA). We examined predisposing risk factors for a subtherapeutic discharge (INR <1.8), including increased body weight, age, gender, end stage renal disease (ESRD), smoking, and peri-operative transfusion. Chart review identified 249 patients for study inclusion. Logistic regression (LR) was used to identify associated risk factors for a subtherapeutic INR (<1.8) on day of discharge. The majority of patients (58.6%, 146 of 249) following TJA surgery were found to have a subtherapeutic INR level (INR<1.8) at discharge (mean length of stay 2.6 days). Multivariate LR analysis found that weight greater than 180 lbs. (OR 2.08, CI 1.09, 3.98, P=0.027) was found to increase the odds of a subtherapeutic INR on day of discharge. Our results were not significant for weight 20% beyond ideal body weight, age (>65y), gender, peri-operative transfusion, smoking, ESRD or autoimmune disease. A patient’s body weight influences response to warfarin following TJA. An inpatient warfarin dosing nomogram that takes into account a patient’s weight should be used to reduce the risk of subtherapeutic INR levels in obese TJA patients.
format Online
Article
Text
id pubmed-4483539
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-44835392015-07-08 Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement Murphy, Ryan Stehli, Annamarie Nguyen, Hiep Leu, Szu-Yun Nguyen, Danh V Schwarzkopf, Ran Open Orthop J Article The purpose of this study was to determine the percentage of patients discharged with a subtherapeutic INR <1.8 using our institutions inpatient warfarin dosing nomogram following total joint arthroplasty (TJA). We examined predisposing risk factors for a subtherapeutic discharge (INR <1.8), including increased body weight, age, gender, end stage renal disease (ESRD), smoking, and peri-operative transfusion. Chart review identified 249 patients for study inclusion. Logistic regression (LR) was used to identify associated risk factors for a subtherapeutic INR (<1.8) on day of discharge. The majority of patients (58.6%, 146 of 249) following TJA surgery were found to have a subtherapeutic INR level (INR<1.8) at discharge (mean length of stay 2.6 days). Multivariate LR analysis found that weight greater than 180 lbs. (OR 2.08, CI 1.09, 3.98, P=0.027) was found to increase the odds of a subtherapeutic INR on day of discharge. Our results were not significant for weight 20% beyond ideal body weight, age (>65y), gender, peri-operative transfusion, smoking, ESRD or autoimmune disease. A patient’s body weight influences response to warfarin following TJA. An inpatient warfarin dosing nomogram that takes into account a patient’s weight should be used to reduce the risk of subtherapeutic INR levels in obese TJA patients. Bentham Open 2015-05-15 /pmc/articles/PMC4483539/ /pubmed/26157529 http://dx.doi.org/10.2174/1874325001509010129 Text en © Murphy et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Murphy, Ryan
Stehli, Annamarie
Nguyen, Hiep
Leu, Szu-Yun
Nguyen, Danh V
Schwarzkopf, Ran
Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement
title Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement
title_full Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement
title_fullStr Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement
title_full_unstemmed Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement
title_short Assessment of Dosing and Patient Factors on the Efficacy of Warfarin Following Total Joint Replacement
title_sort assessment of dosing and patient factors on the efficacy of warfarin following total joint replacement
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483539/
https://www.ncbi.nlm.nih.gov/pubmed/26157529
http://dx.doi.org/10.2174/1874325001509010129
work_keys_str_mv AT murphyryan assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement
AT stehliannamarie assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement
AT nguyenhiep assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement
AT leuszuyun assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement
AT nguyendanhv assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement
AT schwarzkopfran assessmentofdosingandpatientfactorsontheefficacyofwarfarinfollowingtotaljointreplacement